These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2611010)

  • 21. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Community requirements relating to drugs derived from human blood and plasma].
    Brunko P
    Ann Pharm Fr; 1994; 52(2):89-98. PubMed ID: 7944184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical drug development.
    Brodniewicz T; Grynkiewicz G
    Acta Pol Pharm; 2010; 67(6):578-85. PubMed ID: 21229871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationship between pharmaceutical industry and the French government during the last two centuries].
    Bonnemain H; Bonnemain B
    Rev Hist Pharm (Paris); 2002; 50(334):239-56. PubMed ID: 12378715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
    O'Neill RT
    Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Looking forward in pharmaceutical process chemistry.
    Davies IW; Welch CJ
    Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tuberculosis and its control--lessons from the past and future prospect].
    Shimao T
    Kekkaku; 2005 Jun; 80(6):481-9. PubMed ID: 16130906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A vision of the pharmaceutical industry.
    Muñio S
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():5-9. PubMed ID: 9800720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory decisions and the pharmaceutical industry.
    Snell ES
    Med Toxicol; 1986; 1 Suppl 1():130-6. PubMed ID: 3821429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring of national drug policies--regional comparison between Bulgaria, Romania, Macedonia, Bosnia Herzegovina.
    Petrova GI
    Cent Eur J Public Health; 2001 Nov; 9(4):205-13. PubMed ID: 11787250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A decade of fragment-based drug design: strategic advances and lessons learned.
    Hajduk PJ; Greer J
    Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.